The Ledger

TFX

Teleflex IncorporatedHealth Careinsider_universe

Last close $130.88Sep 13, 2026

Day −0.08%

Currently held

Agent 17 — 52-Week High Momentumlong
34 sh @ $142.05 · stop —
-$376.04 unrealized

Everything we've seen

?Sep 14, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 14, 2:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 14, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 14, 2:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 14, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 14, 1:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 14, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 14, 1:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 14, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 14, 12:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 14, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 14, 12:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 14, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 14, 11:21 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 14, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 14, 11:21 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 11, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 11, 3:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 11, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 11, 3:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 11, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 11, 2:21 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 11, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 11, 2:21 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 11, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 11, 1:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 11, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 11, 1:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
?Sep 11, 12:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
!Sep 11, 12:21 PMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
TFX (Teleflex) is a diversified medical device company with generally stable fundamentals, and the 10.7% dip from its 30-day high does not appear tied to any confirmed fundamental impairment — no negative headlines, no earnings miss, and the 8-K filings carry no disclosed adverse metrics. However, the evidence base is extremely thin: no insider buying, no options flow confirmation, no analyst commentary, and no identifiable catalyst for a rebound. The Health Care sector is underperforming SPY on both 5d and 30d bases (-3.26pts and -4.24pts respectively), suggesting this dip is partly sector-driven rather than purely idiosyncratic, which limits the alpha recovery thesis. Earnings are 54 days away (non-factor), and macro rates (10Y at 4.83%, above the ~4.5% structural headwind threshold) create a modest but real headwind for rate-sensitive medical device valuations.
?Sep 11, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
!Sep 11, 12:20 PMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
TFX is down 10.7% from its 30-day high with no identifiable fundamental cause — no guidance cuts, no going-concern language, and no adverse disclosures in the recent 8-K filings. The drop appears sector-driven rather than idiosyncratic, as Health Care (XLV) has meaningfully underperformed SPY by ~4.24pts over 30 days. However, the signal stack is thin: no insider buying, no options flow, and no news to anchor a catalyst thesis. Earnings are 54 days away (clean runway), but the macro backdrop is a headwind — the 10Y at 4.83% (above the 4.5% threshold) and elevated 5Y forward inflation (T5YIFR 1.8σ above trend) both pressure rate-sensitive health care names. Net signal score is approximately +1 (sector underperformance +1, no near-term earnings +1, high 10Y yield -1, absent confirming signals), which is marginal and below the threshold for a confident buy without a cluster insider buy or unusual call flow.
❖Sep 11, 11:40 AMnewsvia finnhub
TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?
?Sep 10, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 3.15% with only 25 minutes remaining until the forced close cutoff. The extremely limited time window is the dominant factor here — even if downside momentum is genuine, there is very little runway for a further -1.5% stop to be avoided or a +3% target to be reached. With only 25 minutes left, late-session dynamics (position squaring, EOD rebalancing) frequently cause partial mean reversion rather than continuation. The macro context (5Y5Y forward inflation 1.6σ above trend) is modestly negative for rate-sensitive sectors, which could include medical device names like TFX, but this is a weak and indirect signal. No headlines provide a fundamental catalyst to anchor continued selling conviction. The move itself is meaningful at -3.15% and suggests real sell-side flow, but the risk/reward of chasing continuation this close to the close — with tight stops and a forced flatten — is unfavorable. The probability of meaningful additional downside in the next 25 minutes does not clear the 0.5 threshold given time constraints alone.
!Sep 10, 3:20 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TFX is down 3.15% with only 25 minutes remaining until the forced close cutoff. The extremely limited time window is the dominant factor here — even if downside momentum is genuine, there is very little runway for a further -1.5% stop to be avoided or a +3% target to be reached. With only 25 minutes left, late-session dynamics (position squaring, EOD rebalancing) frequently cause partial mean reversion rather than continuation. The macro context (5Y5Y forward inflation 1.6σ above trend) is modestly negative for rate-sensitive sectors, which could include medical device names like TFX, but this is a weak and indirect signal. No headlines provide a fundamental catalyst to anchor continued selling conviction. The move itself is meaningful at -3.15% and suggests real sell-side flow, but the risk/reward of chasing continuation this close to the close — with tight stops and a forced flatten — is unfavorable. The probability of meaningful additional downside in the next 25 minutes does not clear the 0.5 threshold given time constraints alone.
?Sep 10, 1:06 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 2.62% intraday with no attributable headline, suggesting either institutional selling or sector rotation rather than a news-driven spike that could reverse quickly. The move is meaningful in magnitude — real flow is present. Macro context shows 5Y5Y forward inflation (T5YIFR) elevated at 1.6σ above trend, which pressures rate-sensitive and growth-oriented names like TFX (a medical device company with moderate rate sensitivity); this backdrop does not favor a reversal. However, with 159 minutes remaining until the forced close, there is ample time for either continuation or mean reversion. No catalyst to drive further selling is identifiable, and without volume confirmation or a clear sector-wide downdraft confirmed, this is a moderate-conviction setup rather than a high-conviction one. The absence of news does not disqualify the trade. Slight lean toward continuation given the size of the move and macro headwinds, but probability stays near the lower range of actionable territory.
!Sep 10, 1:06 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
TFX is down 2.62% intraday with no attributable headline, suggesting either institutional selling or sector rotation rather than a news-driven spike that could reverse quickly. The move is meaningful in magnitude — real flow is present. Macro context shows 5Y5Y forward inflation (T5YIFR) elevated at 1.6σ above trend, which pressures rate-sensitive and growth-oriented names like TFX (a medical device company with moderate rate sensitivity); this backdrop does not favor a reversal. However, with 159 minutes remaining until the forced close, there is ample time for either continuation or mean reversion. No catalyst to drive further selling is identifiable, and without volume confirmation or a clear sector-wide downdraft confirmed, this is a moderate-conviction setup rather than a high-conviction one. The absence of news does not disqualify the trade. Slight lean toward continuation given the size of the move and macro headwinds, but probability stays near the lower range of actionable territory.
?Sep 10, 11:20 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 1.72% today with no attributable news catalyst, suggesting the move is likely technical or broad-market driven rather than a fundamental shock. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for rate-sensitive sectors broadly but TFX (medical devices) has limited direct rate sensitivity in terms of business fundamentals, though higher real rates can pressure valuation multiples. With 265 minutes remaining (roughly 4.4 hours), there is ample time for the move to continue or reverse, so time is not a constraining factor. The absence of news does not disqualify continuation — real selling flow has occurred. However, the move at -1.72% is below the 2% threshold that would signal stronger conviction, and without a clear catalyst or sector-specific macro driver, the setup is borderline. No strong reversal signals are apparent, and the default lean with moderate momentum and time remaining is slight continuation. Probability set at just above threshold given weak but present downward momentum and no countervailing catalyst.
!Sep 10, 11:20 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is down 1.72% today with no attributable news catalyst, suggesting the move is likely technical or broad-market driven rather than a fundamental shock. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is a mild headwind for rate-sensitive sectors broadly but TFX (medical devices) has limited direct rate sensitivity in terms of business fundamentals, though higher real rates can pressure valuation multiples. With 265 minutes remaining (roughly 4.4 hours), there is ample time for the move to continue or reverse, so time is not a constraining factor. The absence of news does not disqualify continuation — real selling flow has occurred. However, the move at -1.72% is below the 2% threshold that would signal stronger conviction, and without a clear catalyst or sector-specific macro driver, the setup is borderline. No strong reversal signals are apparent, and the default lean with moderate momentum and time remaining is slight continuation. Probability set at just above threshold given weak but present downward momentum and no countervailing catalyst.
❖Sep 10, 10:02 AMnewsvia finnhub
Is This the Right Time to Add Neogen Stock to Your Portfolio?
NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
❖Sep 9, 4:18 PMnewsvia finnhub
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: Teleflex (NYSE:TFX) Shines
Looking back on surgical equipment & consumables - specialty stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Teleflex (NYSE:TFX) and its peers.
❖Sep 8, 6:30 AMnewsvia finnhub
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa., September 08, 2026--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026.
❖Sep 4, 10:35 AMnewsvia finnhub
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
❖Sep 4, 6:30 AMnewsvia finnhub
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
WAYNE, Pa., September 04, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with
❖Sep 4, 5:37 AMnewsvia finnhub
Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push
On August 6, Teleflex Incorporated (NYSE:TFX) reported second-quarter results for the period ended June 30, and the numbers told two different stories at once. Revenue from continuing operations climbed to $570.3 million, up 28.9% from a year earlier, while GAAP diluted earnings per share slid to $0.96 from $1.54. Add in a completed divestiture, a […]
?Sep 2, 11:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 2.36% today with no attributable headline, suggesting the move is driven by real institutional flow or sector rotation rather than a news catalyst that might fade quickly. With 255 minutes remaining (roughly 4+ hours), there is ample time for the move to extend to the +3% target. The macro context shows the 5-year forward inflation rate elevated at 1.7σ above trend — this is mildly headwind for rate-sensitive sectors, but TFX (Teleflex, a medical device company) is not primarily rate-sensitive in the same way as REITs or utilities, so the macro drag is limited. Absence of news is not a fade signal per se; a 2.36% move represents meaningful conviction from real size. No reversal pattern is evident from the data provided — price is holding the day's gains rather than fading off morning highs. Light on confirmatory evidence (no volume data, no sector peers context, no news catalyst), which keeps this out of the high-conviction range, but the base case for an intraday momentum trade of this magnitude with significant time remaining is mild continuation. Probability sits modestly above the 0.5 threshold.
!Sep 2, 11:30 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is up 2.36% today with no attributable headline, suggesting the move is driven by real institutional flow or sector rotation rather than a news catalyst that might fade quickly. With 255 minutes remaining (roughly 4+ hours), there is ample time for the move to extend to the +3% target. The macro context shows the 5-year forward inflation rate elevated at 1.7σ above trend — this is mildly headwind for rate-sensitive sectors, but TFX (Teleflex, a medical device company) is not primarily rate-sensitive in the same way as REITs or utilities, so the macro drag is limited. Absence of news is not a fade signal per se; a 2.36% move represents meaningful conviction from real size. No reversal pattern is evident from the data provided — price is holding the day's gains rather than fading off morning highs. Light on confirmatory evidence (no volume data, no sector peers context, no news catalyst), which keeps this out of the high-conviction range, but the base case for an intraday momentum trade of this magnitude with significant time remaining is mild continuation. Probability sits modestly above the 0.5 threshold.
?Aug 6, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [cluster_break_up] For the bulk of the lookback window (2026-07-10 through 2026-07-31), TFX oscillated in a tight $130–$137 band on routine volume averaging roughly 420K shares per day — a classic low-volume price cluster in 2-D PV space. The path then broke decisively to the upside: on 2026-08-03 the close surged to $139.70 on 1.0M shares (more than 2× the prior cluster's typical volume), and today, 2026-08-06, price closed at $139.22 on 2.1M shares — a z-score of 9.82 relative to the 20-day mean of 480K — confirming that the breakout is being met with substantial, not fading, demand. The two-session sequence (Aug 3 + Aug 6) with volume expanding well above the cluster's norms satisfies the SIR multi-session confirmation standard for a cluster_break_up, distinguishing it from a single exhaustion spike. Risks: A close back below the cluster ceiling (~$136–$137) on elevated volume would indicate the breakout has failed and distribution is occurring into the spike; additionally, if today's 2.1M-share session proves to be a one-day liquidity event (e.g., index rebalance or options expiry) with no follow-through buying in the next 2–3 sessions, the PV path would revert to no_pattern territory.
?Aug 6, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 2.49% with no attributable headline, suggesting this is either sector rotation, broader risk-off flow, or quiet distribution. With 354 minutes remaining (essentially most of the trading day still ahead), there is ample time for the move to continue if institutional selling persists. The macro context shows 5Y inflation expectations printing 1.9σ below trend, which is modestly risk-negative and could pressure equities in general, though TFX (Teleflex, medical devices) is not a primary TIPS/gold/energy reactor. The absence of a reversal catalyst or news-driven bounce keeps continuation bias intact, but the lack of a clear sector or macro tailwind for the downside, combined with no volume information to confirm heavy selling conviction, limits confidence. The move is at the lower bound of 'meaningful' (2.49%), and without volume data or a catalyst, this reads as ordinary momentum — probability set at 0.52 reflecting mild continuation lean with no strong reason to fade.
!Aug 6, 9:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is down 2.49% with no attributable headline, suggesting this is either sector rotation, broader risk-off flow, or quiet distribution. With 354 minutes remaining (essentially most of the trading day still ahead), there is ample time for the move to continue if institutional selling persists. The macro context shows 5Y inflation expectations printing 1.9σ below trend, which is modestly risk-negative and could pressure equities in general, though TFX (Teleflex, medical devices) is not a primary TIPS/gold/energy reactor. The absence of a reversal catalyst or news-driven bounce keeps continuation bias intact, but the lack of a clear sector or macro tailwind for the downside, combined with no volume information to confirm heavy selling conviction, limits confidence. The move is at the lower bound of 'meaningful' (2.49%), and without volume data or a catalyst, this reads as ordinary momentum — probability set at 0.52 reflecting mild continuation lean with no strong reason to fade.
?Aug 3, 6:03 PMdecisionconsidered
Agent 20 — SIR Price/Volume — buy
[not executed — reserve_floor_or_cash] [cluster_break_up] For the bulk of the 20-day window (2026-07-07 through 2026-07-31) TFX's PV path was tightly clustered between roughly $130 and $136.71 on routine volume averaging near the 20-day ADV of 428K — a textbook low-volume price consolidation cluster. Today's bar (2026-08-03) broke decisively above that cluster: close $139.72 on 872K shares, a volume z-score of 4.83 and more than 2× the 20-day ADV, constituting a clean cluster_break_up signal. The preceding session (2026-07-31, close $136.71, 558K) already showed above-average up-day volume, giving the breakout at least two sessions of accumulating demand to lean on rather than a pure single-bar event. Risks: A failure to hold above the prior cluster ceiling (~$136–$137) on any near-term pullback — especially if accompanied by above-average down-day volume — would invalidate the break and suggest a false breakout or distribution. Additionally, the elevated 10Y-3M spread (0.92, +1.8σ) signals growing recession risk; a broad risk-off rotation into that macro backdrop could overwhelm the stock-specific technical setup and drag TFX back into the cluster.
?Jul 23, 1:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 2.47% today with no attributable headline, suggesting institutional selling or broader sector pressure rather than news-driven panic that might quickly reverse. The macro context shows a below-trend yield curve (T10Y2Y 1.8σ below trend), which is mildly supportive of defensive/medical device names like TFX in a risk-off sense, but this slight tailwind is not strong enough to confidently expect a reversal given the magnitude of today's move. With 155 minutes remaining, there is meaningful time for further drift. The absence of a catalyst cuts both ways — no catalyst to reverse the move either. The move is consistent with quiet continuation selling into the close. No clear reversal signals are evident. Probability is modest rather than high because the macro context is mildly counter to further selling, volume signals are unknown, and the 2.47% move is at the lower bound of what constitutes a high-conviction momentum setup. Lean slight continuation down.
!Jul 23, 1:10 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is down 2.47% today with no attributable headline, suggesting institutional selling or broader sector pressure rather than news-driven panic that might quickly reverse. The macro context shows a below-trend yield curve (T10Y2Y 1.8σ below trend), which is mildly supportive of defensive/medical device names like TFX in a risk-off sense, but this slight tailwind is not strong enough to confidently expect a reversal given the magnitude of today's move. With 155 minutes remaining, there is meaningful time for further drift. The absence of a catalyst cuts both ways — no catalyst to reverse the move either. The move is consistent with quiet continuation selling into the close. No clear reversal signals are evident. Probability is modest rather than high because the macro context is mildly counter to further selling, volume signals are unknown, and the 2.47% move is at the lower bound of what constitutes a high-conviction momentum setup. Lean slight continuation down.
?Jul 15, 1:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 2.04% today with no attributable headline, suggesting this is driven by organic order flow or sector rotation rather than a news-driven spike. A 2%+ move without a catalyst often reflects institutional accumulation or technical breakout buying, which can persist into the close. The macro context (T10Y2Y at 1.9σ below trend, a flattening curve) is modestly negative for cyclicals but TFX (Teleflex, a medical devices company) is relatively defensive and not directly in the banks or rate-sensitive bucket, so curve shape is a limited headwind here. With 150 minutes remaining, there is ample time for the move to extend toward the +3% profit target. No reversal signals are noted — the current price represents a sustained hold above the open rather than a fade from morning highs. Absent any contrary evidence, the base case is modest continuation of momentum. Probability is set conservatively at 0.54 given the lack of a clear catalyst to sustain aggressive buying, but the asymmetric risk/reward (tight -1.5% stop vs. +3% target) supports taking the trade.
!Jul 15, 1:16 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is up 2.04% today with no attributable headline, suggesting this is driven by organic order flow or sector rotation rather than a news-driven spike. A 2%+ move without a catalyst often reflects institutional accumulation or technical breakout buying, which can persist into the close. The macro context (T10Y2Y at 1.9σ below trend, a flattening curve) is modestly negative for cyclicals but TFX (Teleflex, a medical devices company) is relatively defensive and not directly in the banks or rate-sensitive bucket, so curve shape is a limited headwind here. With 150 minutes remaining, there is ample time for the move to extend toward the +3% profit target. No reversal signals are noted — the current price represents a sustained hold above the open rather than a fade from morning highs. Absent any contrary evidence, the base case is modest continuation of momentum. Probability is set conservatively at 0.54 given the lack of a clear catalyst to sustain aggressive buying, but the asymmetric risk/reward (tight -1.5% stop vs. +3% target) supports taking the trade.
?Jul 14, 6:05 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] After a promising accumulation-like rally from the Jun-22 low ($121.67 / 723K down-day) through Jul-10 ($135.73 / 530K), the PV path has now turned distributive at the top: the two highest closing prices in the window (Jul-10 at $135.73 and Jul-13 at $136.40) were both printed on fading volume (530K and 359K respectively), while today's sharp -4.57% reversal on Jul-14 ($130.16 / 306K) pulls the path back below the Jul-2 breakout close of $133.99 — a classic failure to hold a breakout. Critically, down-day volume has been consistently heavier than up-day volume in the most recent five sessions: Jul-7 (479K down), Jul-8 (267K down), Jul-9 (531K up — the lone exception), Jul-10 (530K up), Jul-13 (359K up), Jul-14 (306K down); the rally into the $134–136 band was built on diminishing buying interest and is now being surrendered on the latest leg down, consistent with SIR's distribution signature of fading up-day volume at price extremes. Risks: A reclaim of the $133.99–$134.32 breakout zone (Jul-2/Jul-6 closes) on volume materially above the 453K ADV would invalidate the distribution read and suggest the Jul-14 drop was a shakeout rather than a top. Additionally, any broader Health Care sector rotation or macro yield-curve steepening (the T10Y2Y is currently 1.9σ below trend, which historically precedes curve normalization) could provide a tailwind that overrides the weak near-term PV structure.
?Jul 9, 3:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 3.44% intraday, which is a meaningful move with real conviction behind it. However, several factors weigh against continuation into the close: (1) Only 25 minutes remain, severely limiting runway for further gains toward the +3% profit target from current levels — the forced 3:45 PM flatten compresses the opportunity window considerably. (2) No supporting news catalyst is identifiable, meaning this move could be institutional flow that has already largely completed. (3) The macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is generally unfavorable for broad risk-on continuation and may create headwinds for late-session momentum. (4) After a 3.44% surge with no news, the risk of mean-reversion or profit-taking in the final 25 minutes is elevated — late-session fading of morning/midday spikes on no-news moves is a common pattern. TFX is a medical device company (defensives-adjacent), which could see some pressure in a bear-flattening macro environment. The combination of very limited time remaining and elevated fade risk in the absence of a clear catalyst pushes the probability just below the 0.5 threshold.
!Jul 9, 3:20 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
TFX is up 3.44% intraday, which is a meaningful move with real conviction behind it. However, several factors weigh against continuation into the close: (1) Only 25 minutes remain, severely limiting runway for further gains toward the +3% profit target from current levels — the forced 3:45 PM flatten compresses the opportunity window considerably. (2) No supporting news catalyst is identifiable, meaning this move could be institutional flow that has already largely completed. (3) The macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is generally unfavorable for broad risk-on continuation and may create headwinds for late-session momentum. (4) After a 3.44% surge with no news, the risk of mean-reversion or profit-taking in the final 25 minutes is elevated — late-session fading of morning/midday spikes on no-news moves is a common pattern. TFX is a medical device company (defensives-adjacent), which could see some pressure in a bear-flattening macro environment. The combination of very limited time remaining and elevated fade risk in the absence of a clear catalyst pushes the probability just below the 0.5 threshold.
?Jul 9, 2:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 4.07% intraday with no attributable headline, suggesting institutional flow rather than a news-driven spike that might fade quickly. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) With 90 minutes remaining, there is moderate but not ample time — enough for continuation but also enough for a late-session fade. (2) The macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is modestly supportive of defensives but TFX (Teleflex, a medical devices company) is not a core rate-sensitive name, so macro tailwind is neutral at best. (3) No catalysts identified means we cannot rule out this being a one-sided morning squeeze that exhausts before the close. (4) A 4%+ move with no news raises the possibility of a gap-and-fade pattern if buyers have already been satisfied. On balance, the absence of a clear fade signal and the system's bounded risk profile (tight stop, fixed target) tip this to a slight continuation bias, but conviction is modest.
!Jul 9, 2:16 PMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
TFX is up 4.07% intraday with no attributable headline, suggesting institutional flow rather than a news-driven spike that might fade quickly. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) With 90 minutes remaining, there is moderate but not ample time — enough for continuation but also enough for a late-session fade. (2) The macro context shows a flattening yield curve (T10Y2Y at 2.1σ below trend), which is modestly supportive of defensives but TFX (Teleflex, a medical devices company) is not a core rate-sensitive name, so macro tailwind is neutral at best. (3) No catalysts identified means we cannot rule out this being a one-sided morning squeeze that exhausts before the close. (4) A 4%+ move with no news raises the possibility of a gap-and-fade pattern if buyers have already been satisfied. On balance, the absence of a clear fade signal and the system's bounded risk profile (tight stop, fixed target) tip this to a slight continuation bias, but conviction is modest.
?Jul 8, 12:10 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down ~2% intraday with no attributable news headline, suggesting the move is driven by internal flow or quiet sector rotation rather than a catalyst. The macro context shows T10Y2Y at 0.36, notably below trend, which tends to pressure cyclical/industrial-leaning names like TFX (medical devices, more defensive) less acutely, but a flattening yield curve is not a tailwind either. With 215 minutes remaining there is ample time for continuation, but the absence of a clear catalyst and no news flow means there is limited informational edge to call strong follow-through. The move magnitude (~2%) is at the lower boundary of meaningful conviction — real but not definitively forceful. No reversal pattern is visible from the data provided, and no volume alarm is triggered. Net assessment: modest lean toward continuation given time remaining and no fade signal, but conviction is low — probability sits just above the 0.5 threshold.
!Jul 8, 12:10 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is down ~2% intraday with no attributable news headline, suggesting the move is driven by internal flow or quiet sector rotation rather than a catalyst. The macro context shows T10Y2Y at 0.36, notably below trend, which tends to pressure cyclical/industrial-leaning names like TFX (medical devices, more defensive) less acutely, but a flattening yield curve is not a tailwind either. With 215 minutes remaining there is ample time for continuation, but the absence of a clear catalyst and no news flow means there is limited informational edge to call strong follow-through. The move magnitude (~2%) is at the lower boundary of meaningful conviction — real but not definitively forceful. No reversal pattern is visible from the data provided, and no volume alarm is triggered. Net assessment: modest lean toward continuation given time remaining and no fade signal, but conviction is low — probability sits just above the 0.5 threshold.
?Jun 30, 10:21 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 1.78% today with no attributable headline catalyst, suggesting the move is driven by either broader market pressure or quiet institutional selling. The macro backdrop shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, which is a dovish inflation signal — generally supportive of long-duration/growth assets, so this macro context does not reinforce selling pressure in TFX specifically, nor does it provide a strong fade catalyst. With 325 minutes remaining (essentially a full afternoon session), there is ample time for the move to continue or reverse. The move at 1.78% is meaningful but not extreme — it sits just below the 2% threshold where momentum tends to be more self-sustaining. Absence of news cuts both ways: no headline to reverse sentiment, but also no fundamental anchor to hold sellers in. On balance, the modest downside momentum with significant time remaining and no clear reversal signal gives a slight edge to continuation, but conviction is low. Setting probability at 0.51 — minimal edge to the downside, consistent with taking the trade given the system's bounded risk parameters.
!Jun 30, 10:21 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is down 1.78% today with no attributable headline catalyst, suggesting the move is driven by either broader market pressure or quiet institutional selling. The macro backdrop shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, which is a dovish inflation signal — generally supportive of long-duration/growth assets, so this macro context does not reinforce selling pressure in TFX specifically, nor does it provide a strong fade catalyst. With 325 minutes remaining (essentially a full afternoon session), there is ample time for the move to continue or reverse. The move at 1.78% is meaningful but not extreme — it sits just below the 2% threshold where momentum tends to be more self-sustaining. Absence of news cuts both ways: no headline to reverse sentiment, but also no fundamental anchor to hold sellers in. On balance, the modest downside momentum with significant time remaining and no clear reversal signal gives a slight edge to continuation, but conviction is low. Setting probability at 0.51 — minimal edge to the downside, consistent with taking the trade given the system's bounded risk parameters.
!Jun 29, 9:51 AMsignal
options_momentum — insufficient_capital
?Jun 24, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 2.36% intraday with no attributable headline, suggesting institutional or systematic flow rather than a news-driven spike that might fade quickly. The move is meaningful in magnitude — real size drove this. Macro context shows T10YIE at 2.0σ below 24-month trend (lower inflation expectations), which is broadly supportive of risk assets and long-duration sensitive sectors, giving a mild tailwind. However, with 320 minutes remaining (over 5 hours), the move has had time to develop and could be maturing — fading into the close is possible if early buyers take profits. No reversal pattern is explicitly noted, and no negative catalyst is present. The setup is modest continuation momentum with a neutral-to-supportive macro backdrop but no strong catalyst to sustain the move. Assigning a slight edge to continuation given the lack of fade signals and the bounded risk structure of the trade.
!Jun 24, 10:25 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
TFX is up 2.36% intraday with no attributable headline, suggesting institutional or systematic flow rather than a news-driven spike that might fade quickly. The move is meaningful in magnitude — real size drove this. Macro context shows T10YIE at 2.0σ below 24-month trend (lower inflation expectations), which is broadly supportive of risk assets and long-duration sensitive sectors, giving a mild tailwind. However, with 320 minutes remaining (over 5 hours), the move has had time to develop and could be maturing — fading into the close is possible if early buyers take profits. No reversal pattern is explicitly noted, and no negative catalyst is present. The setup is modest continuation momentum with a neutral-to-supportive macro backdrop but no strong catalyst to sustain the move. Assigning a slight edge to continuation given the lack of fade signals and the bounded risk structure of the trade.
?Jun 23, 3:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 5 minutes remaining until the forced 3:45 PM ET close, there is virtually no runway for continuation regardless of momentum quality. The 2.03% move is meaningful and represents real conviction, but the time constraint is the dominant factor here — even a strong setup cannot materially extend in 5 minutes of trading. No headlines provide a catalyst to sustain flow, and the macro context (low inflation expectations, long-duration sensitivity) is mildly supportive but not a near-term driver. The primary reason to fade is purely mechanical: the position would be forced flat almost immediately, leaving essentially no time for the +3% target to be reached while the -1.5% stop remains a live risk during end-of-day volatility. Probability set below 0.5 solely due to the time constraint.
!Jun 23, 3:40 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
With only 5 minutes remaining until the forced 3:45 PM ET close, there is virtually no runway for continuation regardless of momentum quality. The 2.03% move is meaningful and represents real conviction, but the time constraint is the dominant factor here — even a strong setup cannot materially extend in 5 minutes of trading. No headlines provide a catalyst to sustain flow, and the macro context (low inflation expectations, long-duration sensitivity) is mildly supportive but not a near-term driver. The primary reason to fade is purely mechanical: the position would be forced flat almost immediately, leaving essentially no time for the +3% target to be reached while the -1.5% stop remains a live risk during end-of-day volatility. Probability set below 0.5 solely due to the time constraint.
?Jun 23, 8:51 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$121.67.
?Jun 23, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a well-established medical device company with a historically stable business model, and there is no confirmed fundamental impairment visible in the evidence — no negative headlines, no earnings miss, and no insider sales. The ~10.9% drop from the 30-day high lacks an identifiable catalyst, suggesting it may be macro/sector-driven rather than company-specific. Healthcare (XLV) has underperformed SPY by ~2.79pts over 5 days, consistent with a broad sector rotation rather than idiosyncratic TFX weakness, which moderately supports a mean-reversion thesis.
?Jun 23, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$121.67.
▣Jun 22, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.54 (-$64.08)
Stop: premium $2.54 ≤ trailing floor $2.55 (peak $3.40 × 0.75)
?Jun 22, 7:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.30 cash available; close=$121.67.
?Jun 22, 7:21 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
TFX (Teleflex) is a well-established medical device company with diversified product lines and a historically stable balance sheet, suggesting the ~11% drop from its 30-day high is more likely macro/sector-driven than a fundamental deterioration. No news headlines or material financial metrics from the recent 8-K filings are available to indicate a catalyst such as a guidance cut, earnings miss, or accounting issue. The macro backdrop shows 5-year inflation expectations running 1.5σ below trend, which may be contributing to broader healthcare/medical device sector rotation rather than company-specific weakness.
?Jun 22, 6:06 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a well-established medical device company with a historically stable business model, and there is no confirmed fundamental impairment visible in the evidence — no negative headlines, no earnings miss, and no insider sales. The ~10.9% drop from the 30-day high lacks an identifiable catalyst, suggesting it may be macro/sector-driven rather than company-specific. Healthcare (XLV) has underperformed SPY by ~2.79pts over 5 days, consistent with a broad sector rotation rather than idiosyncratic TFX weakness, which moderately supports a mean-reversion thesis.
✓Jun 22, 1:19 PMdecisionacted
options_momentum — decide: buy
PUT on TFX — 5-day return -6.33% with close below 20-day MA ($129.39). IV 30.8%. Sized 1 contract(s) at $3.18 premium.
?Jun 22, 11:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down 4.33% intraday with no headline catalyst visible, suggesting this is likely institutional selling or a sector-driven rotation rather than a news-driven spike that might reverse quickly. A move of this magnitude represents real conviction and flow. With 285 minutes remaining (essentially the full afternoon session), there is ample time for continuation. The macro context — 5-year inflation expectations running 1.5σ below trend — is modestly risk-off in character and does not favor a bounce in medical device names like TFX, which carry some interest-rate and growth sensitivity. No reversal signals (fades off highs, news-driven capitulation spike) are evident from available data. The absence of news is not a disqualifier per framework guidance. The setup is ordinary momentum with no strong reversal catalyst, placing this in the 0.5–0.65 range. Slight caution applied because without volume data it's difficult to confirm whether the selling pressure is sustained versus thin, nudging the probability to the lower end of that band.
▣Jun 21, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.77 (-$121.00)
Stop: premium $2.77 ≤ trailing floor $2.99 (peak $3.98 × 0.75)
▢Jun 21, 8:00 PMjournal
options_momentum opened long 100 @ $3.18
✓Jun 17, 3:18 PMdecisionacted
options_momentum — decide: buy
PUT on TFX — 5-day return -5.46% with close below 20-day MA ($130.29). IV 29.3%. Sized 1 contract(s) at $3.98 premium.
▣Jun 16, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.46 (-$92.66)
Stop: premium $2.46 ≤ trailing floor $2.54 (peak $3.39 × 0.75)
▢Jun 16, 8:00 PMjournal
options_momentum opened long 100 @ $3.98
✓Jun 16, 10:34 AMdecisionacted
options_momentum — decide: buy
PUT on TFX — 5-day return -6.68% with close below 20-day MA ($130.62). IV 30.0%. Sized 1 contract(s) at $3.39 premium.
▢Jun 15, 8:00 PMjournal
options_momentum opened long 100 @ $3.39
▣Jun 9, 8:00 PMjournalstop
options_momentum closed long 100 @ $2.89 (-$166.84)
Stop: premium $2.89 ≤ trailing floor $3.48 (peak $4.64 × 0.75)
✓Jun 9, 6:04 PMdecisionacted
options_momentum — decide: buy
CALL on TFX — 5-day return 8.27% with close above 20-day MA ($130.65). IV 25.3%. Sized 1 contract(s) at $4.56 premium.
?Jun 9, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up ~2% intraday with no attributable headline, suggesting real institutional flow rather than a news-driven spike prone to fading. The move is meaningful but not extreme, sitting at the lower end of the 2-5% range where continuation is plausible. With 350 minutes remaining (~5.8 hours), there is ample time for the move to extend into the close — time is not a limiting factor here. The macro context (T10Y2Y at 2σ below trend, flattish/slightly inverted curve) is somewhat favorable for defensive/healthcare names like TFX, as the macro brief flags defensives as reactive to bear-flattening dynamics. No reversal signals or thin-volume flags are evident from the available data. In the absence of a clear catalyst or sector headwind, the base case is modest continuation of the morning momentum. Probability is set conservatively at 0.54 — above the action threshold but not a high-conviction setup, reflecting the lack of a strong directional catalyst and the absence of volume confirmation data.
❖Jun 9, 2:33 AMnewsvia finnhub
Teleflex Presents 4‑Yr Follow‑Up Data From First-in-Human BIOMAG-I Clinical Study At EuroPCR Conference
Persistently Low Target Lesion Failure and No New Cardiac-Related EventTeleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the
❖Jun 8, 8:02 PMnewsvia finnhub
Piper Sandler Upgrades Teleflex (TFX)
▢Jun 8, 8:00 PMjournal
options_momentum opened long 100 @ $4.56
❖Jun 8, 9:44 AMnewsvia finnhub
Piper Sandler Upgrades Teleflex to Overweight, Raises Price Target to $160
Piper Sandler analyst Matt O'Brien upgrades Teleflex (NYSE:TFX) from Neutral to Overweight and raises the price target from $140 to $160.
?Jun 8, 9:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 1.68% today, a modest but real move reflecting genuine buying interest. There are no headlines to explain the move, but absence of news doesn't disqualify continuation — this could be sector rotation, index-related flow, or position accumulation. The macro context (T10Y2Y at 0.38, 2.5σ below trend) mildly favors defensive/medtech names like TFX as investors seek yield-curve-insensitive sectors, which is a modest tailwind. With 365 minutes remaining (essentially a full trading day remaining until the 3:45 ET cutoff), there is ample time for the move to extend or at least hold. The move size of ~1.68% is below the 2-5% 'high conviction' threshold, so I treat it as ordinary momentum without strong directional pressure either way. No reversal signals are evident from the data provided. Baseline continuation probability applies — lean slightly positive given time remaining and macro context supportive of defensives.
?Jun 4, 9:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is up 2.65% intraday with no attributable headline, suggesting this is likely flow-driven or technical in nature. The move is meaningful and represents real conviction from a sized participant. With 405 minutes remaining (well over 6 hours — likely this is early-to-mid session), there is ample time for continuation. However, several factors temper enthusiasm: (1) No news catalyst means the move could be institutional repositioning that is largely complete. (2) The macro context (T10Y2Y at 2.1σ below trend, bear-flattening pressure) is more favorable for defensives broadly, which could be a mild tailwind for TFX as a medical device/healthcare name, but the flattening signal is not strongly directional for this specific ticker. (3) Absence of any confirming headlines or sector catalyst makes it harder to assign high conviction. Overall, the base case is modest continuation — the move has size and momentum behind it, the time remaining is substantial, and there is no obvious fade trigger. Assigning 0.54 reflects ordinary momentum without strong reason to reverse, consistent with taking a measured long position with tight stop protection.
▣Jun 3, 8:00 PMjournalstop
options_momentum closed long 100 @ $132.21 (+$12,866.67)
intraday stop sweep
?Jun 3, 9:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
TFX is down ~1.83% intraday with no news catalyst identified. The move is meaningful but sits below the 2-5% threshold that would indicate unusually strong conviction flow. With 400 minutes remaining (well over a full session equivalent, suggesting this is early-to-mid session), there is ample time for continuation but also for mean reversion. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening bias) mildly favors defensives, and TFX (Teleflex, a medical device company) is a defensive/healthcare name — this macro backdrop would typically provide some support, acting as a mild headwind against further downside continuation. No headlines exist to anchor the move to a durable catalyst, making the selloff potentially flow-driven or sector rotation rather than fundamental. Balancing the modest momentum signal against the defensive sector tailwind from the macro context and absence of a news driver, this is a borderline read. Assigning 0.5 — the minimum threshold to trigger a position — reflecting genuine uncertainty with no strong reason to expect either continuation or reversal.
?Jun 3, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.42 cash available; close=$125.24.
?Jun 3, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
TFX (Teleflex) is a well-established medical device company with no confirmed fundamental impairment visible in the evidence — the drop appears to be sector-driven, as Health Care (XLV) is underperforming SPY by ~7.87pts over 30 days, suggesting the 10.3% decline is largely a sector-wide move rather than idiosyncratic deterioration. However, the evidence base is extremely thin: no news headlines, no meaningful metrics from SEC filings, no insider activity, and no options flow, leaving the thesis built almost entirely on the absence of bad news rather than the presence of positive catalysts. The 10Q was filed for Q1 2026 but carries no extractable metrics, and two recent 8-Ks provide no informational signal.
✓Jun 3, 7:01 AMdecisionacted
options_momentum — decide: buy
PUT on TFX — 5-day return -5.04% with close below 20-day MA ($129.67). IV 31.9%. Sized 1 contract(s) at $4.22 premium.
▢Jun 2, 8:00 PMjournal
options_momentum opened long 100 @ $3.54
❖Jun 1, 3:46 AMnewsvia finnhub
Teleflex Commences $500M Senior Notes Due 2032 Offering
Teleflex Incorporated (NYSE: TFX) ("Teleflex") announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the "Notes"), subject to market and other

← Back to dashboard